BFRI - Biofrontera Inc. Stock Price, Fair Value and News

1.07USD-0.02 (-1.83%)Market Closed

Market Summary

USD1.07-0.02

Market Closed

-1.83%

BFRI Stock Price

View Fullscreen

BFRI RSI Chart

BFRI Valuation

Market Cap

5.4M

Price/Earnings (Trailing)

-0.24

Price/Sales (Trailing)

0.16

EV/EBITDA

-0.07

Price/Free Cashflow

-0.22

BFRI Price/Sales (Trailing)

BFRI Profitability

EBT Margin

-69.41%

Return on Equity

426.33%

Return on Assets

-93.96%

Free Cashflow Yield

-451.24%

BFRI Fundamentals

BFRI Revenue

Revenue (TTM)

33.3M

Rev. Growth (Yr)

-9.4%

Rev. Growth (Qtr)

-25.32%

BFRI Earnings

Earnings (TTM)

-23.1M

Earnings Growth (Yr)

-39.57%

Earnings Growth (Qtr)

-396%

Breaking Down BFRI Revenue

Last 7 days

-15.1%

Last 30 days

-37.4%

Last 90 days

42.7%

Trailing 12 Months

-88.5%

How does BFRI drawdown profile look like?

BFRI Financial Health

Current Ratio

1.44

BFRI Investor Care

Shares Dilution (1Y)

281.24%

Diluted EPS (TTM)

-10.25

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2024	33.3M	0	0	0
2023	27.7M	29.0M	33.6M	34.1M
2022	29.1M	27.7M	27.7M	28.7M
2021	20.2M	21.5M	22.8M	24.1M
2020	0	0	22.5M	18.8M
2019	0	0	0	26.2M

Get all data in R, Python etc through our Historical Stock Data APIs

Tracking the Latest Insider Buys and Sells of Biofrontera Inc.

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
May 18, 2023	monaco erica l.	acquired	-	-	76,336	chief executive officer
May 18, 2023	luebbert hermann	acquired	-	-	95,420	executive chairman
Aug 22, 2022	luebbert hermann	acquired	-	-	113,379	executive chairman
Jul 01, 2022	monaco erica l.	acquired	-	-	56,689	chief executive officer

Which funds bought or sold BFRI recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
May 15, 2024	MORGAN STANLEY	sold off	-100	-554	-	-%
May 15, 2024	BANK OF AMERICA CORP /DE/	sold off	-100	-1.00	-	-%
May 15, 2024	BANK OF AMERICA CORP /DE/	sold off	-100	-30.00	-	-%
May 15, 2024	Tower Research Capital LLC (TRC)	reduced	-39.96	-5,855	2,934	-%
May 15, 2024	Royal Bank of Canada	unchanged	-	-	-	-%
May 15, 2024	CITADEL ADVISORS LLC	new	-	374	374	-%
May 14, 2024	AIGH Capital Management LLC	new	-	766,203	766,203	0.23%
May 14, 2024	SCOTIA CAPITAL INC.	new	-	61,600	61,600	-%
May 13, 2024	RENAISSANCE TECHNOLOGIES LLC	new	-	16,000	16,000	-%
May 13, 2024	XTX Topco Ltd	new	-	18,765	18,765	-%

Are Funds Buying or Selling BFRI?

Are funds buying BFRI calls or puts?

Calls

Puts

No. of funds holding Calls - Puts

Net Call Options

No. of funds that own BFRI

No. of Funds

Unveiling Biofrontera Inc.'s Major ShareHolders

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
May 07, 2024	hewlett fund lp	9.9%	504,168	SC 13G
Mar 20, 2024	lytton laurence w	9.99%	508,886	SC 13G
Mar 20, 2024	hirschman orin	9.9%	501,434	SC 13G
Mar 20, 2024	rosalind advisors, inc.	9.9%	504,261	SC 13G
Mar 20, 2024	rosalind advisors, inc.	9.9%	504,261	SC 13G
Mar 15, 2024	bigger capital, llc	4.9%	251,377	SC 13G
Feb 14, 2024	armistice capital, llc	9.99%	168,105	SC 13G
Nov 04, 2022	abshagen consulting gmbh	11.8%	3,148,042	SC 13G
Sep 19, 2022	deutsche balaton aktiengesellschaft	5.00%	1,177,676	SC 13D/A
Aug 25, 2022	deutsche balaton aktiengesellschaft	3.55%	835,734	SC 13D

Recent SEC filings of Biofrontera Inc.

View All Filings

Date Filed	Form Type	Document
May 15, 2024	10-Q	Quarterly Report
May 15, 2024	8-K	Current Report
May 09, 2024	EFFECT	EFFECT
May 07, 2024	SC 13G	Major Ownership Report
May 03, 2024	8-K	Current Report
May 03, 2024	S-1	Initial Public Offering
Apr 30, 2024	8-K	Current Report
Apr 30, 2024	DEFR14A	DEFR14A
Apr 25, 2024	8-K	Current Report
Apr 22, 2024	EFFECT	EFFECT

Peers (Alternatives to Biofrontera Inc.)

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
JNJ	372.2B	85.6B	6.82%	-1.69%	9.67	4.35	5.68%	202.39%
MRK	332.3B	61.4B	4.65%	15.09%	144.1	5.41	6.11%	-82.30%
AMGN	167.7B	29.5B	18.35%	39.38%	44.55	5.68	12.76%	-52.47%
PFE	162.3B	57.8B	12.71%	-21.46%	129.52	2.81	76.51%	-86.81%
GILD	84.4B	27.4B	1.23%	-13.37%	174.21	3.07	1.51%	-91.32%
TEVA	18.4B	16.0B	23.52%	97.09%	-37.29	1.15	7.23%	71.10%
MID-CAP
ALKS	4.1B	1.7B	0.67%	-19.91%	9.41	2.37	54.01%	364.56%
PRGO	4.1B	4.6B	-0.70%	-10.77%	-528.11	0.89	-0.06%	94.55%
BHC	2.5B	9.0B	-21.94%	-21.03%	-5.45	0.28	10.01%	-27.45%
AMPH	2.1B	676.2M	8.56%	-0.82%	13.75	3.14	30.38%	66.04%
SMALL-CAP
TLRY	1.5B	743.2M	15.12%	-18.85%	-4.35	2.06	24.65%	80.36%
TXMD	25.8M	1.3M	18.52%	-47.17%	-3.49	19.84	-98.14%	-104.71%
ACRX	18.4M	89.6M	6.93%	25.60%	-1.29	0.19	287.27%	-129.41%
AGRX	2.5M	21.5M	2.70%	-90.89%	-0.32	0.12	66.16%	61.83%
ACOR	633.5K	115.7M	-50.00%	-97.38%	0	0.01	-2.22%	-352.48%

Biofrontera Inc. News

Latest updates

Biofrontera Inc. Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)

Income Statement (Quarterly)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2019Q4
Revenue	-25.3%	7,912,000	10,595,000	8,896,000	5,848,000	8,733,000	10,144,000	4,322,000	4,457,000	9,751,000	9,167,500	4,334,000	5,855,000	4,744,000	3,998,000	3,252,000	-
Operating Expenses	-7.5%	13,379,000	14,460,500	13,516,000	14,547,000	14,225,000	15,764,000	7,961,000	10,669,000	12,861,000	11,048,000	20,439,000	9,542,000	8,272,000	-	5,596,000	-
S&GA Expenses	-100.0%	-	9,100,500	8,619,000	11,456,000	9,800,000	10,087,000	7,765,000	9,669,000	7,616,000	9,106,000	17,090,000	5,552,000	4,758,000	-	4,191,000	-
R&D Expenses	-48.5%	17,000	33,000	33,000	11,000	-	-	-	-	-	-	-	-	-	-	-	-
EBITDA Margin	-24.1%	-0.75	-0.60	-0.79	-0.78	-0.50	-0.02	-0.45	-0.93	-0.99	-1.57	-0.60	-0.64	-0.68	-0.73	-	-
Interest Expenses	-563.7%	-1,407,000	-212,000	-142,000	-79,000	-35,000	-35,000	-89,000	-38,000	-33,000	-89,000	-86,000	-85,000	-84,000	-	-744,000	-
Income Taxes	116.7%	1,000	-6,000	1,000	14,000	5,000	1,000	1,000	-	30,000	5,000	6,000	44,000	1,000	-	61,000	-
Earnings Before Taxes	-396.5%	-10,436,000	3,520,000	-6,341,000	-9,823,000	-7,473,000	-2,784,000	-2,565,000	-850,000	5,591,000	-14,500,500	-16,006,000	-3,617,000	-3,533,000	-	-2,924,000	-
EBT Margin	-17.6%	-0.69	-0.59	-0.79	-0.78	-0.49	-0.02	-0.44	-0.93	-0.98	-1.56	-0.48	-0.51	-0.54	-0.58	-	-
Net Income	-396.0%	-10,437,000	3,526,000	-6,342,000	-9,837,000	-7,478,000	-2,785,000	-2,566,000	-850,000	5,561,000	-14,505,500	-16,012,000	-3,661,000	-3,534,000	-	-2,985,000	-
Net Income Margin	-17.5%	-0.69	-0.59	-0.79	-0.78	-0.49	-0.02	-0.45	-0.93	-0.98	-1.56	-0.48	-0.51	-0.54	-0.58	-	-
Free Cashflow	62.0%	-3,382,000	-8,891,000	-2,000,000	-10,300,000	-3,714,000	-8,300,000	-5,914,000	-	-	-	-	-	-	-	-	-

Balance Sheet

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Balance Sheet															(In Thousands)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2019Q4
Assets	-12.0%	24,575	27,932	34,104	36,905	41,965	50,884	55,059	53,626	49,202	53,219	15,354	18,282	21,210	24,138	28,752
Current Assets	-12.7%	20,155	23,075	29,611	32,296	37,223	43,140	48,493	46,981	42,531	46,421	10,137	-	-	19,576	23,468
Cash Equivalents	184.2%	3,817	1,343	3,422	4,453	13,505	17,208	27,518	31,913	22,428	24,545	1,716	-	-	8,080	7,302
Inventory	-36.7%	6,905	10,908	16,068	14,785	6,670	7,168	12,087	8,808	4,872	4,458	5,439	-	-	7,091	10,480
Net PPE	-10.4%	120	134	154	175	197	204	224	248	245	267	289	-	-	370	503
Liabilities	14.2%	26,421	23,139	33,066	29,732	25,214	27,006	32,464	36,393	31,786	41,881	32,734	27,926	23,118	18,310	58,931
Current Liabilities	-22.4%	14,036	18,088	29,124	25,352	20,450	20,894	17,143	14,876	12,359	13,836	11,291	-	-	4,420	11,742
Short Term Borrowings	-39.7%	2,355	3,904	-	-	-	-	-	-	-	-	-	-	-	-	-
Shareholder's Equity	-213.0%	-5,416	4,793	1,038	7,173	16,751	23,878	22,595	17,233	17,416	11,338	-	-	2,294	5,828	-
Retained Earnings	-10.4%	-110,087	-99,700	-103,176	-96,800	-86,997	-79,519	-76,734	-74,200	-73,300	-78,879	-64,400	-	-	-41,166	-30,179
Additional Paid-In Capital	0.2%	104,666	104,441	104,213	103,980	103,721	103,396	99,306	91,382	90,717	90,216	46,986	-	-	46,986	-
Shares Outstanding	235.4%	5,089	1,518	1,368	1,368	1,335	1,335	978	898	855	855	400	400	400	400	-
Float	-	-	-	-	14,200	-	-	-	35,400	36,800	-	-	-	-	-	-

Cashflow (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Cashflow (Quarterly)																(In Thousands)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2019Q4
Cashflow From Operations	62.6%	-3,325	-8,900	-2,000	-10,300	-3,700	-8,299	-5,913	113	-2,100	-20,990	-1,225	-1,100	-3,400	-	-	-
Share Based Compensation	0%	228	228	207	259	351	383	401	551	517	-	-	-	-	-	-	-
Cashflow From Investing	-100.0%	-	73.00	382	178	-14.00	-2,086	-3,034	-31.00	-5.00	-9.00	1.00	-	-	-	-	-
Cashflow From Financing	-13.6%	5,799	6,714	591	1,106	-	-	4,630	-	-	43,829	-121	-	-	-	-	-

Get Full Access to Grufity – and Unlimited Downloads

Gain full access to fair value, watchlists, stock screener, unlimited page visits, and additional features by joining as a member today for just $1.99.

Try For Just $1.99

BFRI Income Statement

2024-03-31

Condensed Consolidated Statements of Operations - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
Defined Benefit Plan Disclosure [Line Items]
Products revenues, net	$ 7,901	$ 8,715
Revenues, related party	11	18
Total revenues, net	7,912	8,733
Operating expenses
Selling, general and administrative, related party	(4)	27
Research and development	17
Change in fair value of contingent consideration		(200)
Total operating expenses	13,379	14,225
Loss from operations	(5,467)	(5,492)
Other income (expense)
Change in fair value of warrant liabilities	(3,429)	1,028
Change in fair value of investment, related party	3	(2,941)
Loss on debt extinguishment	(316)
Interest expense, net	(1,407)	(35)
Other income (expense), net	180	(33)
Total other income (expense)	(4,969)	(1,981)
Loss before income taxes	(10,436)	(7,473)
Income tax expense	1	5
Net loss	(10,437)	(7,478)
Related Party [Member]
Operating expenses
Cost of revenues	3,946	4,547
Nonrelated Party [Member]
Operating expenses
Cost of revenues	170	51
Selling, general and administrative	$ 9,250	$ 9,800

BFRI Balance Sheet

2024-03-31

Condensed Consolidated Balance Sheets - USD ($) $ in Thousands	Mar. 31, 2024	Dec. 31, 2023
Current assets:
Cash and cash equivalents	$ 3,817	$ 1,343
Accounts receivable, net	3,520	5,162
Inventories, net	6,905	10,908
Prepaid expenses and other current assets	560	425
Total current assets	20,155	23,075
Property and equipment, net	120	134
Operating lease right-of-use assets	1,416	1,612
Intangible asset, net	2,556	2,629
Other assets	328	482
Total assets	24,575	27,932
Current liabilities:
Operating lease liabilities	690	691
Accrued expenses and other current liabilities	4,230	4,487
Short term debt	2,355	3,904
Total current liabilities	14,036	18,088
Long-term liabilities:
Warrant liabilities	11,731	4,210
Operating lease liabilities, non-current	621	804
Other liabilities	33	37
Total liabilities	26,421	23,139
Commitments and contingencies (Note 17)
Stockholders’ equity:
Preferred Stock, $0.001 par value, 19,978,828 shares authorized, zero shares issued and outstanding as of March 31, 2024 and December 31, 2023
Common Stock, $0.001 par value, 15,000,000 shares authorized; 5,089,413 and 1,517,628 shares issued and outstanding as of March 31, 2024 and December 31, 2023	5	2
Additional paid-in capital	104,666	104,441
Accumulated deficit	(110,087)	(99,650)
Total stockholders’ equity	(5,416)	4,793
Total liabilities, mezzanine equity and stockholders’ equity	24,575	27,932
Series B1 Preferred Stock [Member]
Mezzanine equity:
Series B-1 Convertible Preferred Stock, $0.001 par value, 6,586 share authorized, 4,806 and zero shares issued and outstanding as of March 31, 2024 and December 31, 2023, respectively	3,570
Related Party [Member]
Current assets:
Investment, related party	23	78
Other receivables, related party	171
Other assets, related party	5,159	5,159
Current liabilities:
Accounts payable, related parties	4,044	5,698
Nonrelated Party [Member]
Current liabilities:
Accounts payable, related parties	$ 2,717	$ 3,308

About Biofrontera Inc.

Biofrontera Inc., a biopharmaceutical company, engages in the commercialization of pharmaceutical products for the treatment of dermatological conditions in the United States. The company offers Ameluz, a prescription drug; and the RhodoLED lamp series for photodynamic therapy for the lesion-directed and field-directed treatment of actinic keratosis of mild-to-moderate severity on the face and scalp. It also Xepi, a prescription drug for the treatment of impetigo. The company was founded in 1997 and is headquartered in Woburn, Massachusetts.

CEO	Dr. Hermann Luebbert Ph.D.
WEBSITE	biofrontera-us.com
INDUSTRY	Pharmaceuticals
EMPLOYEES	81

Biofrontera Inc. Frequently Asked Questions

What is the ticker symbol for Biofrontera Inc.? What does BFRI stand for in stocks?

BFRI is the stock ticker symbol of Biofrontera Inc.. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Biofrontera Inc. (BFRI)?

As of Fri May 17 2024, market cap of Biofrontera Inc. is 5.45 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of BFRI stock?

You can check BFRI's fair value in chart for subscribers.

What is the fair value of BFRI stock?

You can check BFRI's fair value in chart for subscribers. The fair value of Biofrontera Inc. is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Biofrontera Inc. is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for BFRI so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Biofrontera Inc. a good stock to buy?

The fair value guage provides a quick view whether BFRI is over valued or under valued. Whether Biofrontera Inc. is cheap or expensive depends on the assumptions which impact Biofrontera Inc.'s fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for BFRI.

What is Biofrontera Inc.'s Price to Earnings (PE) and Price to sales (PS) ratio?

As of Fri May 17 2024, BFRI's PE ratio (Price to Earnings) is -0.24 and Price to Sales (PS) ratio is 0.16. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. BFRI PE ratio will change depending on the future growth rate expectations of investors.